Sage Therapeutics boosted by strong results in Phase III trial

7 January 2019

Sage Therapeutics (Nasdaq: SAGE) is trading up over 50% in New York today, after the firm announced positive Phase III results for its novel central nervous system (CNS) therapy SAGE-217.

The top-line data comes from the ROBIN study, which is evaluating the effects of the therapy on people with postpartum depression (PPD) who have depressive symptoms.

After two weeks of out-patient treatment, people treated with SAGE-217 had a statistically-significant improvement of 17.8 points according to a commonly-used score, compared to 13.6 points for those treated with placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK